Associated Papers
Molecular Mechanisms Underlying Single Nucleotide Polymorphism-Induced Reactivity Decrease in CYP2D6.
Becker D et al.
Journal of Chemical Information and Modeling, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M et al.
European Journal of Human Genetics : Ejhg, 2022
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Benchmarking analysis of deleterious SNP prediction tools on CYP2D6 enzyme.
Ferreira KCDV et al.
Chemical Biology & Drug Design, 2020
Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.
Kasi PM et al.
Technology in Cancer Research & Treatment, 2019
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro.
Su Y et al.
Canadian Journal of Physiology and Pharmacology, 2016
Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms In Vitro.
Cai J et al.
Basic & Clinical Pharmacology & Toxicology, 2016
Pharmacogenetics of healthy volunteers in Puerto Rico.
Claudio-Campos K et al.
Drug Metabolism and Personalized Therapy, 2015
In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population.
Dai DP et al.
Basic & Clinical Pharmacology & Toxicology, 2015
In vitro assessment of the allelic variants of cytochrome P450.
Hiratsuka M
Drug Metabolism and Pharmacokinetics, 2012
Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.
Teh LK et al.
Drug Metabolism and Pharmacokinetics, 2012
Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T et al.
Current Drug Metabolism, 2011
Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.
Gaedigk A et al.
European Journal of Clinical Pharmacology, 2010
New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B et al.
Drug Metabolism Reviews, 2009
A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6.
Klein K et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2007
Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D et al.
Proteins, 2005